Last updated: September 7, 2026
Shingrix is GSK’s recombinant zoster vaccine and one of the company’s largest growth products. Its commercial trajectory has been driven by expanded adult vaccination recommendations, catch-up demand, strong efficacy, and limited near-term competition. Sales increased from approximately £2.0 billion in 2021 to £3.45 billion in 2023. GSK’s 2024 results showed continued growth, although the rate is expected to moderate as U.S. catch-up vaccination matures and the product enters a more stable recurring-demand phase.[1][2]
The main long-term risks are market saturation in older U.S. adults, lower international vaccination rates, payer and government purchasing pressure, and eventual competition involving recombinant zoster vaccines or biosimilar-like biologic products. Shingrix’s complex antigen-adjuvant manufacturing process and regulatory status make rapid generic substitution unlikely.
What is Shingrix and how does it work?
Shingrix is a non-live, recombinant vaccine containing glycoprotein E antigen combined with GSK’s AS01B adjuvant system. It is administered as a two-dose intramuscular series.
The vaccine received U.S. Food and Drug Administration approval on October 20, 2017, for prevention of herpes zoster in adults aged 50 years and older.[3] FDA later expanded the indication to adults aged 18 years and older who are or will be immunodeficient or immunosuppressed because of disease or therapy.[4]
Unlike the discontinued live vaccine Zostavax, Shingrix does not contain live varicella-zoster virus. Its commercial positioning rests on high efficacy, durable protection, and use in immunocompromised adults.
| Attribute |
Shingrix |
| Manufacturer |
GSK |
| Active vaccine component |
Recombinant varicella-zoster virus glycoprotein E |
| Adjuvant |
AS01B |
| Product type |
Recombinant, non-live vaccine |
| U.S. approval |
October 2017 |
| Primary indication |
Prevention of herpes zoster |
| Standard schedule |
Two doses |
| U.S. adult population |
Age 50 and older; certain immunocompromised adults age 18 and older |
| FDA regulatory category |
Biologic licensed under a BLA |
| U.S. product code |
Shingrix, BLA 125614 |
How have Shingrix sales changed over time?
Shingrix sales have increased sharply since launch, with the strongest growth occurring after expanded recommendations and the withdrawal of Zostavax from the U.S. market.
| Fiscal year |
Approximate reported Shingrix sales |
Primary growth drivers |
| 2018 |
£784 million |
Initial U.S. launch and high adult demand |
| 2019 |
£1.84 billion |
Broader U.S. adoption and supply normalization |
| 2020 |
£1.72 billion |
COVID-19 disruption and reduced vaccination visits |
| 2021 |
About £2.0 billion |
Recovery in adult immunization |
| 2022 |
£2.96 billion |
Catch-up vaccination and expanded demand |
| 2023 |
£3.45 billion |
U.S. and international growth |
| 2024 |
Continued growth reported by GSK |
Higher vaccination coverage, international expansion, and recurring demand |
The 2020 decline reflected pandemic-related disruption rather than product-specific weakness. Sales accelerated in 2021 and 2022 as routine vaccination resumed and U.S. adults returned for delayed doses.[1]
GSK reported Shingrix sales of £3.45 billion in 2023, an increase of roughly 17% from 2022 on a reported basis. Shingrix was one of the principal contributors to GSK’s vaccine portfolio performance and a major offset to declining sales from older products.[1]
Why did Shingrix become a major GSK product?
The product benefited from five commercial factors:
- The Centers for Disease Control and Prevention recommended Shingrix for all adults aged 50 years and older.
- CDC recommended it for immunocompromised adults aged 19 years and older.
- Shingrix replaced Zostavax as the principal U.S. shingles vaccine.
- Medicare Part D coverage supported access for the primary older-adult population.
- The two-dose regimen created repeat demand within the same vaccination course.
CDC recommends two doses for immunocompetent adults aged 50 years and older and for immunocompromised adults aged 19 years and older. The second dose is generally administered two to six months after the first, with a shorter interval permitted for certain immunocompromised patients.[5]
What is the Shingrix market size and growth outlook?
The addressable market is large but increasingly mature in the United States. The commercial opportunity includes:
- U.S. adults aged 50 years and older who remain unvaccinated.
- Immunocompromised adults aged 19 years and older.
- Adults who received only one dose.
- International populations with low shingles-vaccine penetration.
- Revaccination or booster opportunities if future clinical guidance supports them.
The United States remains the largest market because of its high reimbursement levels, established pharmacy vaccination infrastructure, and strong physician and public-health recommendations. International growth is more dependent on national immunization programs, private-pay affordability, and government procurement.
The most important medium-term change is a shift from catch-up vaccination to steady incidence-based demand. During the launch and post-Zostavax period, many sales came from adults who had never been vaccinated. As coverage rises, annual demand should increasingly reflect newly eligible adults, delayed second doses, immunocompromised patients, and international expansion.
What limits the Shingrix growth rate?
The main constraints are:
- High U.S. vaccination coverage among the oldest and most health-engaged adults.
- Lower willingness to complete a two-dose schedule.
- Out-of-pocket access problems for some commercially insured or underinsured adults.
- Public-sector pricing pressure.
- Lower vaccine uptake outside the United States.
- Competition for pharmacy and physician administration capacity.
- Potential demand pull-forward from earlier catch-up campaigns.
GSK’s financial trajectory therefore depends less on continued rapid U.S. volume growth and more on maintaining pricing, expanding international access, improving completion of the two-dose series, and sustaining demand among younger immunocompromised adults.
When does Shingrix lose exclusivity?
Shingrix’s principal U.S. regulatory exclusivity is expected to run through October 2029, based on the 12-year reference-product exclusivity period for a licensed biologic beginning with FDA approval on October 20, 2017.[3][6]
| Exclusivity category |
Shingrix status |
| FDA biologic reference-product exclusivity |
Expected through October 2029 |
| Small-molecule Hatch-Waxman exclusivity |
Not applicable |
| Orange Book listing |
Not the principal U.S. biologic framework |
| Purple Book reference product |
Applicable biologic reference-product framework |
| Pediatric exclusivity |
No separate extension should be assumed without a specific FDA-recognized award |
| Patent expiry |
Depends on individual GSK patent families and any term adjustments |
The October 2029 date is a regulatory exclusivity milestone, not an automatic market-entry date. A competitor may need to complete clinical, analytical, manufacturing, and facility requirements before commercial launch. Patent protection, manufacturing rights, regulatory review, and injunctions may extend practical market protection beyond the end of regulatory exclusivity.
What patents protect Shingrix?
Shingrix is protected by a layered intellectual-property position rather than a single composition patent. Relevant protection may include:
- Glycoprotein E antigen constructs.
- Recombinant production methods.
- AS01 adjuvant components.
- Antigen-adjuvant combinations.
- Formulation and stability.
- Manufacturing and purification processes.
- Methods of preventing herpes zoster.
- Dosing regimens for older and immunocompromised adults.
The most commercially important barriers are likely to be combination and manufacturing claims involving the glycoprotein E antigen and AS01B adjuvant. AS01B is a complex adjuvant system containing monophosphoryl lipid A and QS-21 in a liposomal formulation. Reproducing the finished product requires more than copying an antigen sequence.
Public patent analysis must distinguish between:
- Patent families owned by GSK or its affiliates.
- Third-party rights relating to QS-21 or other adjuvant components.
- Patent term adjustments.
- Patent-term extensions.
- Foreign patent expiry dates.
- Claims that remain enforceable after prosecution amendments.
- Manufacturing know-how that is not fully disclosed in issued patents.
Because Shingrix is a biologic vaccine, the relevant U.S. regulatory reference is the Purple Book and the Public Health Service Act, not the standard Orange Book listing process used for small-molecule drugs.[6][7]
What is the Orange Book status of Shingrix?
Shingrix is not primarily protected through an Orange Book patent listing. It is licensed under a biologics license application, or BLA, and its regulatory exclusivity is governed by the Public Health Service Act.
The FDA’s Purple Book identifies reference biological products and biosimilar products. Unlike the Orange Book, the Purple Book does not provide the same standardized, product-level patent-certification framework used in abbreviated new drug applications.[7]
This distinction affects competitive timing. A potential Shingrix competitor would not normally enter through an ordinary ANDA with a Paragraph IV certification.
Are there Paragraph IV challenges to Shingrix?
No major public Paragraph IV challenge has established a generic Shingrix entry pathway. Paragraph IV litigation is associated with the Hatch-Waxman framework for small-molecule drugs. Shingrix is a biologic vaccine, so any follow-on competitor would generally need to use a biosimilar or other biologic approval pathway rather than file a standard ANDA.
A future biosimilar applicant could face:
- Reference-product exclusivity through 2029.
- Patent disputes under the Biologics Price Competition and Innovation Act.
- Analytical comparability requirements.
- Clinical immunogenicity and safety requirements.
- Complex adjuvant characterization.
- Manufacturing-site inspection and validation requirements.
- Supply and cold-chain requirements.
What generic or biosimilar entry risks exist for Shingrix?
Near-term generic substitution risk is low. Shingrix is not a conventional tablet with a readily substitutable active ingredient. The product contains a recombinant antigen and a proprietary adjuvant system, and its performance depends on manufacturing consistency and formulation controls.
The more realistic competitive risks are:
- A new recombinant zoster vaccine with a different antigen or adjuvant.
- A biosimilar-like product that satisfies FDA requirements after reference exclusivity.
- A lower-priced public-sector vaccine that gains favorable procurement status.
- A next-generation vaccine with fewer doses or improved durability.
- Expansion of alternative shingles-prevention technologies.
Any competitor would need to demonstrate an acceptable immune response and safety profile, but it may not need to reproduce every aspect of Shingrix’s formulation if it follows an independent biologic development program.
Which companies are challenging Shingrix?
No company has become a large-scale U.S. commercial challenger to Shingrix in the recombinant zoster-vaccine market. Merck’s Zostavax was the principal prior competitor, but Merck discontinued Zostavax in the United States in 2020 after supply constraints and declining demand.[8]
The competitive landscape currently consists of:
| Competitor category |
Current risk to Shingrix |
| Zostavax |
No meaningful current U.S. commercial threat |
| Generic vaccine manufacturers |
Low near-term risk |
| Biosimilar developers |
Limited public activity; possible after regulatory exclusivity |
| New recombinant vaccines |
Strategic long-term risk |
| Public-sector procurement competitors |
Moderate international risk |
| Next-generation shingles vaccines |
Potentially significant long-term risk |
How does Shingrix compare with Zostavax?
| Category |
Shingrix |
Zostavax |
| Vaccine type |
Recombinant, non-live |
Live attenuated |
| Doses |
Two |
One |
| U.S. launch |
2017 |
2006 |
| U.S. status |
Commercially available |
Discontinued |
| Use in immunocompromised adults |
Recommended for eligible adults |
Contraindicated in many immunocompromised patients |
| Efficacy profile |
Higher and more durable in pivotal studies |
Lower and declined with age |
| Commercial position |
Market leader |
Exited U.S. market |
Shingrix’s two-dose requirement creates an adherence burden, but its efficacy and suitability for immunocompromised adults support its market leadership.
What FDA regulatory milestones affect Shingrix?
| Date |
Milestone |
| October 20, 2017 |
FDA approval for adults aged 50 years and older |
| 2018 |
CDC recommendation for routine vaccination of adults aged 50 years and older |
| 2021 |
FDA expansion to immunocompromised adults aged 18 years and older |
| 2021 |
CDC recommendation for immunocompromised adults aged 19 years and older |
| 2020 |
U.S. discontinuation of Zostavax |
| October 2029 |
Expected end of 12-year reference-product exclusivity |
FDA and CDC milestones have had a direct effect on market adoption. The immunocompromised indication expanded the eligible population and reduced reliance on the older-adult market alone.[3][4][5]
What is GSK’s revenue exposure to Shingrix?
Shingrix is material to GSK’s consolidated revenue and central to the company’s vaccine strategy. Its sales are concentrated in a single product, which creates both operating leverage and concentration risk.
The product’s financial contribution is strengthened by:
- High gross-margin potential for an established vaccine.
- Strong brand recognition.
- Limited U.S. competition.
- Repeat demand from the two-dose series.
- Use across pharmacy, physician, and public-health channels.
- A large installed base of eligible adults.
The principal financial risks are pricing erosion, lower U.S. vaccination volumes, production constraints, and a shift from catch-up demand to maintenance demand. A sharp decline in Shingrix sales would have a disproportionate effect on GSK’s vaccines segment because the product is one of its largest individual brands.
GSK has also used the vaccine portfolio to balance volatility in respiratory and specialty medicines. Shingrix revenue has provided a relatively durable cash-flow stream while GSK has managed other portfolio transitions.
How strong is the Shingrix patent and commercial estate?
The Shingrix estate is commercially strong but not invulnerable.
Strengths
- Twelve years of U.S. biologic exclusivity from approval.
- Complex antigen-adjuvant product architecture.
- High manufacturing barriers.
- Strong clinical differentiation from Zostavax.
- Established CDC recommendations.
- Broad reimbursement and pharmacy distribution.
- No established generic substitution mechanism.
Weaknesses
- The core biologic exclusivity period ends in 2029.
- Some patent claims may expire before or after the regulatory exclusivity date.
- Antigen and adjuvant technologies may face validity and scope challenges.
- International exclusivity is fragmented by country.
- A new vaccine could compete without infringing every Shingrix patent.
- Market growth depends increasingly on unvaccinated populations that are harder to reach.
Overall, Shingrix has a strong commercial moat through the late 2020s. Its post-2029 position will depend more heavily on manufacturing know-how, brand strength, clinical evidence, procurement contracts, and the timing of competing vaccines.
What are the most likely Shingrix launch scenarios?
| Scenario |
Timing |
Commercial effect |
| Continued branded growth |
2025-2028 |
Moderate growth from international expansion and remaining U.S. catch-up demand |
| Mature U.S. market |
2027 onward |
Slower volume growth and greater dependence on replacement demand |
| First follow-on biologic or new vaccine |
After regulatory and patent review |
Selective price pressure, likely limited initial substitution |
| Broad competitive entry |
After 2029 |
Potential erosion in U.S. price and share |
| Next-generation vaccine launch |
Timing uncertain |
Risk of accelerated decline if dosing or durability is materially better |
A rapid generic-style collapse is unlikely. Vaccine markets typically transition through procurement and clinical adoption cycles rather than immediate pharmacy substitution.
Key Takeaways
- Shingrix is GSK’s leading recombinant zoster vaccine and a major revenue contributor.
- Sales rose from roughly £2.0 billion in 2021 to £3.45 billion in 2023.
- U.S. growth is shifting from catch-up vaccination toward recurring adult and immunocompromised demand.
- FDA biologic reference-product exclusivity is expected to run through October 2029.
- Shingrix is governed primarily by the BLA, Purple Book, and Public Health Service Act, not the standard Orange Book and Paragraph IV framework.
- Near-term generic risk is low because of the product’s recombinant antigen, AS01B adjuvant, and complex manufacturing process.
- The principal long-term risks are market saturation, pricing pressure, new recombinant vaccines, and post-2029 follow-on biologic competition.
- GSK’s commercial moat is strongest through the late 2020s, while the post-2029 outcome depends on patent scope, manufacturing barriers, and competitive product quality.
FAQs
Is Shingrix a biologic drug or a vaccine?
Shingrix is a recombinant biologic vaccine licensed under a BLA. It is not a conventional small-molecule drug.
Can a generic company make a generic version of Shingrix?
A standard generic version is unlikely because Shingrix is a biologic vaccine with a recombinant antigen and proprietary adjuvant system. A future competitor would more likely pursue a biosimilar or an independently developed vaccine.
Does Shingrix have Orange Book patents?
Shingrix is not primarily managed through the Orange Book. Its principal regulatory protections arise under the biologic framework, including BLA exclusivity and potential patent rights.
What happens to Shingrix after 2029?
After the expected end of FDA reference-product exclusivity in 2029, follow-on biologic applications or competing vaccines may become more commercially feasible. Entry would still depend on patent disputes, FDA review, manufacturing validation, and market access.
Is GSK financially dependent on Shingrix?
Shingrix is not GSK’s only material product, but it is one of the company’s largest brands and a major contributor to vaccine revenue. A sustained sales decline would materially affect GSK’s growth profile and vaccine-segment earnings.
References
-
GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-report/
-
GSK plc. (2025). Full-year results 2024. https://www.gsk.com/en-gb/investors/financial-results/
-
U.S. Food and Drug Administration. (2017). FDA approves new vaccine to prevent shingles in adults aged 50 and older. https://www.fda.gov/news-events/press-announcements/fda-approves-new-vaccine-prevent-shingles-adults-50-and-older
-
U.S. Food and Drug Administration. (2021). FDA expands approval of Shingrix to include adults aged 18 years and older who are or will be at increased risk of herpes zoster. https://www.fda.gov/
-
Centers for Disease Control and Prevention. (2024). Shingles vaccination. https://www.cdc.gov/shingles/vaccination/
-
U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products. https://www.fda.gov/drugs/development-resources/frequently-asked-questions-biosimilar-development-and-approval
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
Merck & Co., Inc. (2020). Merck to discontinue production and sale of Zostavax in the United States. https://www.merck.com/news/